Ipharmasupports LLC

Ipharmasupports LLC, a Denver-based small business subchapter S corporation, provides radiochemical synthesis equipment, consumables, and maintenance services to federal biomedical research institutions as a prime contractor exclusively — all 49 recent awards carry no subcontractor footprint. The company specializes in F-18 FDOPA synthesis kits, TRASIS radiosynthesis module maintenance and consumables, F-DOPA cassettes, and radiolabeling services supporting positron emission tomography (PET) research programs across the NIH ecosystem. Ipharmasupports does not compete under set-aside categories; all awards are full-and-open or sole-source on merit, reflecting its position as the sole U.S. vendor authorized by TRASIS to provide equipment maintenance services.

Customer concentration is absolute: the National Institutes of Health Clinical Center accounts for 42 of 49 awards ($2.2 million of $2.7 million combined potential value), with the National Heart Lung and Blood Institute, National Cancer Institute, National Institute of Mental Health, and the NIH Office of Logistics and Acquisition Operations together representing the remaining seven awards. The Clinical Center's dominance reflects Ipharmasupports' specialized expertise in PET research infrastructure. Recent representative awards include a $242 thousand sole-source firm fixed-price purchase order (January 2025 through December 2026) from NIH Clinical Center for preventative maintenance and operational qualification on six TRASIS modules; a $198.8 thousand contract (August 2023 through April 2024) for radiolabeling services; a $226.2 thousand purchase order (June 2022) for an ALL IN ONE 18 synthesizer system; and a $41.6 thousand order (May 2026) from the National Institute of Mental Health for TRASIS unit rebuild and three-year service agreements.

Activity has fluctuated modestly — six awards in 2022 declining to three in 2024, with four awards in 2025 and three in 2026 year-to-date. Three awards totaling $308 thousand in combined potential value reach ultimate completion inside the next twenty-four months, exposing modest recompete risk. The vendor operates primarily through blanket purchase agreements: 20 task orders under BPA 75N90018A00004 carry $331 thousand combined potential value, and one task order under the Indefinite Delivery Contract 75N90019D00013 carries $14 thousand. The company's award portfolio clusters under NAICS 311999 (Pharmaceutical Preparation Manufacturing) at 25 awards, with secondary exposure under NAICS 541690 (Other Scientific and Technical Consulting Services) at ten awards and surgical and medical instrument manufacturing. PSC coding centers on Laboratory Equipment and Supplies (39 awards) with subordinate medical and surgical instruments exposure.